Last edition
News about "Vas Narasimhan"
Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.
Vas Narasimhan | 22/12/2025 | By News Bureau
Novartis Breaks Ground on Flagship Manufacturing Hub in North Carolina
Novartis has officially begun construction of its flagship manufacturing hub in North Carolina, reinforcing its commitment to end-to-end production of key medicines for US patients. The project, highlighted by FDA Commissioner Marty Makary and Governor Josh Stein, underscores Novartis’ ongoing investment and growth in the US pharmaceutical sector.
Vas Narasimhan | 15/12/2025 | By News Bureau
Novartis Opens New Radioligand Therapy Plant in California under USD 23 Billion US Expansion Plan
Novartis has inaugurated its third US-based radioligand therapy (RLT) manufacturing facility in Carlsbad, California, expanding its production network to meet growing demand and maintain a 99.9 percent on-time delivery rate for patients across the western United States, Alaska, and Hawaii.
Vas Narasimhan | 12/11/2025 | By Dineshwori | 134
Novartis agrees to acquire Avidity Biosciences
Novartis has announced a definitive agreement to acquire Avidity Biosciences, a move aimed at expanding its neuroscience portfolio with advanced programs targeting rare genetic neuromuscular disorders.
Vas Narasimhan | 27/10/2025 | By Dineshwori | 127
Novartis Unveils USD 23 Billion US Investment to Boost Domestic Drug Manufacturing and Research
Over the next 5 years, Novartis will establish 1 biomedical research innovation hub in San Diego, CA, its second global R&D hub in the US.
Vas Narasimhan | 11/04/2025 | By Abha | 561
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy